S Vadhan-Raj
Overview
Explore the profile of S Vadhan-Raj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
918
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, et al.
Blood Cancer J
. 2016 Jan;
6:e378.
PMID: 26745852
In a phase 3 trial of denosumab vs zoledronic acid in patients (n=1776) with bone metastases and solid tumors or multiple myeloma, denosumab was superior to zoledronic acid for the...
2.
Lipton A, Fizazi K, Stopeck A, Henry D, Smith M, Shore N, et al.
Eur J Cancer
. 2015 Dec;
53:75-83.
PMID: 26693901
Background: Analyses of phase III trials showed that denosumab was superior to zoledronic acid (ZA) in preventing skeletal-related events (SREs) irrespective of age, history of SREs, or baseline pain status....
3.
Vadhan-Raj S, von Moos R, Fallowfield L, Patrick D, Goldwasser F, Cleeland C, et al.
Ann Oncol
. 2012 Aug;
23(12):3045-3051.
PMID: 22851406
Background: Patients with metastatic bone disease are living longer in the metastatic stage due to improvements in cancer therapy, making strategies to prevent the aggravation of bone disease and its...
4.
Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, et al.
Ann Oncol
. 2011 Oct;
23(6):1640-5.
PMID: 22015451
Background: Tumor lysis syndrome (TLS) is a life-threatening disorder characterized by hyperuricemia and metabolic derangements. The efficacy of rasburicase, administered daily for 5 days, has been well established. However, the...
5.
Vadhan-Raj S
Oncology (Williston Park)
. 2001 Aug;
15(7 Suppl 8):35-8.
PMID: 11497230
Recombinant human thrombopoietin (rhTPO) is a full-length glycosylated molecule that has been under evaluation in the setting of chemotherapy-induced myelosuppression. It has been shown to be a potent stimulator of...
6.
Grazziutti M, Przepiorka D, Rex J, Braunschweig I, Vadhan-Raj S, Savary C
Bone Marrow Transplant
. 2001 Apr;
27(6):647-52.
PMID: 11319596
Lymphocytes play a major role in host defense against Aspergillus, but little is known about the contribution of dendritic cells (DC) to antifungal immunity in humans. We have observed that...
7.
Jones Jr D, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, et al.
Stem Cells
. 2000 Sep;
16 Suppl 2:199-206.
PMID: 11012192
Patients undergoing anticancer therapy are often at risk for developing severe and/or prolonged posttreatment thrombocytopenia. This can be associated with significant bleeding; currently, it is treated with supportive platelet transfusions....
8.
Vadhan-Raj S
Semin Hematol
. 2000 Jun;
37(2 Suppl 4):28-34.
PMID: 10831286
Since the identification and cloning of c-Mpl ligand, two forms of recombinant human thrombopoietin have undergone clinical development. Both the full-length molecule, known as rhTPO, and the truncated version of...
9.
Vadhan-Raj S, Verschraegen C, Bueso-Ramos C, Broxmeyer H, Kudelka A, Freedman R, et al.
Ann Intern Med
. 2000 Feb;
132(5):364-8.
PMID: 10691586
Background: Thrombocytopenia is a significant problem in the treatment of cancer. Objective: To assess the clinical safety of therapy with recombinant human thrombopoietin (rhTPO) and its ability to ameliorate chemotherapy-induced...
10.
Vadhan-Raj S, Currie L, Bueso-Ramos C, Livesey S, Connor J
Br J Haematol
. 1999 Mar;
104(2):403-11.
PMID: 10050726
Chemotherapy-induced thrombocytopenia represents a significant clinical problem in the management of patients with malignancy. Recombinant human thrombopoietin (rhTPO) is a potent stimulator of platelet production in vivo. The ability to...